{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:47:46Z","timestamp":1698302866280},"reference-count":14,"publisher":"Wiley","issue":"S54","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":5623,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1993,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> The spectrum of microorganisms responsible for infection in neutropenic patients has changed in the last decade, with Gram\u2010positive organisms now predominant. New antibiotic strategies have been required and have evolved to cope with this change. In particular, the optimal timing of glycopeptide antibiotic use has been addressed. Both teicoplanin and vancomycin are highly effective agents for susceptible Gram\u2010positive organisms. Teicoplanin has advantages in terms of ease of administration and lower toxicity, while vancomycin has proved durable over many years' use. There are now firm indications for the use of glycopeptide antibiotics in febrile neutropenic patients, including clinically defined central venous catheter infection and microbiologically documented infection with susceptible organisms. The empirical use of the glycopeptide antibiotics in combination with other agents as first\u2010line treatment, however, is less certain. The utility of this approach remains controversial and ultimately depends on the extent to which local practice favours the emergence of Gram\u2010positive infections in neutropenic patients.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1993.tb01902.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T19:12:20Z","timestamp":1279480340000},"page":"25-28","source":"Crossref","is-referenced-by-count":0,"title":["Teicoplanin in combination: role in the management of the febrile neutropenic patient"],"prefix":"10.1111","volume":"51","author":[{"given":"J.","family":"Davies","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/27.suppl_B.51"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.8.1193"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/25.6.985"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.451"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92530-3"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.4.672"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01642100"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07928.x"},{"key":"e_1_2_1_10_2","volume-title":"Teicoplanin vs vancomycin as empiric therapy in febrile neutropenic patients","author":"Martino P","year":"1991"},{"key":"e_1_2_1_11_2","volume-title":"Ceftriaxone and teicoplanin as initial therapy for febrile neutropenic patients and bone marrow transplant recipients","author":"Fauser AA","year":"1991"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.11.2246"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.1126"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/21.suppl_A.105"},{"key":"e_1_2_1_15_2","volume-title":"A once a day antimicrobial therapy: teicoplanin and ceftriaxone in the treatment of febrile neutropenic children with acute leukaemia","author":"Schaison G","year":"1988"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1993.tb01902.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1993.tb01902.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T18:19:23Z","timestamp":1698257963000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1993.tb01902.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,12]]},"references-count":14,"journal-issue":{"issue":"S54","published-print":{"date-parts":[[1993,12]]}},"alternative-id":["10.1111\/j.1600-0609.1993.tb01902.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1993.tb01902.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,12]]}}}